Mol Cancer Ther Publishes Bexmarilimab Research
Faron Pharmaceuticals Ltd. (“Faron” or “Company”) Molecular Cancer Therapeutics Publishes Research on the Nonclinical Characterization of Bexmarilimab Press release, May 9, 2022 at 02:00 AM (EDT) / 07:00 AM (BST) / 09:00 AM (EEST) TURKU, FINLAND / BOSTON, MA – Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, today announces that the American Association for Cancer Research (AACR)